Is Burning Rock Biotech Ltd (BNR) Halal?

NASDAQ Healthcare China $176M
✗ NOT HALAL
Confidence: 90/100
Burning Rock Biotech Ltd (BNR) is Not Halal under AAOIFI Standard 21. While the debt ratio of 21.8% is acceptable, the cash and interest-bearing securities ratio of 217.0% exceeds the 30% threshold. Burning Rock Biotech Ltd operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 21.8%
/ 30%
217.0%
/ 30%
72.4%
/ 30%
2.37%
/ 5%
✗ NOT HALAL
DJIM 21.8%
/ 33%
217.0%
/ 33%
72.4%
/ 33%
2.37%
/ 5%
✗ NOT HALAL
MSCI 5.9%
/ 33%
58.7%
/ 33%
19.6%
/ 33%
2.37%
/ 5%
✗ NOT HALAL
S&P 21.8%
/ 33%
217.0%
/ 33%
72.4%
/ 33%
2.37%
/ 5%
✗ NOT HALAL
FTSE 5.9%
/ 33%
58.7%
/ 33%
19.6%
/ 50%
2.37%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.74
P/B Ratio
2.2
EV/EBITDA
-369.8
EV: $1.3B
Revenue
$516M
Growth: 0.2%
Beta
1.4
High volatility
Current Ratio
3.0

Profitability

Gross Margin 74.7%
Operating Margin -9.5%
Net Margin -10.3%
Return on Equity (ROE) -9.9%
Return on Assets (ROA) -4.0%

Cash Flow & Balance Sheet

Operating Cash Flow-$92M
Free Cash Flow-$98M
Total Debt$52M
Debt-to-Equity8.1
Current Ratio3.0
Total Assets$885M

Price & Trading

Last Close$18.50
50-Day MA$27.12
200-Day MA$15.01
Avg Volume24K
Beta1.4
52-Week Range
$2.18
$41.72

About Burning Rock Biotech Ltd (BNR)

CEO
Mr. Yusheng Han
Sector
Healthcare
Industry
Diagnostics & Research
Country
China
Exchange
NASDAQ
Market Cap
$176M
Currency
USD

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Burning Rock Biotech Ltd (BNR) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Burning Rock Biotech Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Burning Rock Biotech Ltd's debt ratio?

Burning Rock Biotech Ltd's debt ratio is 21.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.9%.

What are Burning Rock Biotech Ltd's key financial metrics?

Burning Rock Biotech Ltd has a market capitalization of $176M, and revenue of $516M. The company maintains a gross margin of 74.7% and a net margin of -10.3%. Return on equity stands at -9.9%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.